Alacrity Care
Alacrity Care is an early-stage health technology company that builds the CloudOnc® digital biomarker platform for AI-powered immunotoxicity monitoring in oncology patients, serving healthcare providers, pharmaceutical companies, and clinical trial sponsors via a B2B2C model.
- Company typePrivate
- Founded2012
- HeadquartersLos Angeles, United States
- Headcount1–10
- GTM typeB2B
- OfferingSoftware
What Alacrity Care does
Alacrity Patient Services, Inc., doing business as Alacrity Care, is an early-stage health technology company headquartered in Los Angeles, California. Founded by medical oncologist David Berz, drawing on his outreach work in Eldoret, Kenya, the company focuses on monitoring and managing immune-related adverse events in cancer patients undergoing immunotherapy. Its core product is the CloudOnc® Digital Companion Platform, a first-in-class digital biomarker platform designed to detect and triage immunotoxicity in oncology patients.
The CloudOnc platform combines continuous patient data collection with AI-powered analytics that surface serious adverse events approximately 6-12 hours ahead of conventional detection and low-grade adverse events more than 24 hours ahead. The platform is supported by 24/7 licensed oncology practitioners, embedding a clinical services layer into the software. Alacrity Care operates a B2B2C model in which products are provided free to patients and monetized through pharmaceutical companies, healthcare industry partners, and clinical trial sponsors. The platform has been deployed to hundreds of oncology patients and is structured around three product lines: the digital companion, a Patient Monitoring Service for outpatient oncology, and a Clinical Trials Support offering for trial sponsors and research institutions. The company is actively hiring across clinical operations, engineering, and research roles to scale the platform.
Alacrity Care firmographics
Firmographics- Name
- Alacrity Care
- Legal name
- Alacrity Patient Services, Inc.
- Website
- https://alacrity.care
- Company type
- Private
- Founded year
- 2012
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Short description
- Alacrity Care is an early-stage health technology company that builds the CloudOnc® digital biomarker platform for AI-powered immunotoxicity monitoring in oncology patients, serving healthcare providers, pharmaceutical companies, and clinical trial sponsors via a B2B2C model.
- Ownership category
- akta.pro rank
Alacrity Care industry classification
Industry- Product category
- Digital Health Oncology Platform
- NAICS
- Computer Systems Design and Related Services (54151), Custom Computer Programming Services (541511)
- SIC
- Services-Health Services (8000), Services-Prepackaged Software (7372)
- akta.pro primary industry
- Oncology Remote Symptom Monitoring & Care Navigation (HLALAFAD)
- akta.pro secondary industries
- Oncology Telemedicine Platforms (HLALAGAH), Clinical Trial Management Systems (CTMS) (HLACAOAD)
Keywords
Where Alacrity Care is headquartered
LocationHeadquarters
- HQ city
- Los Angeles
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
Alacrity Care business model
Business model- GTM type
- B2B
- Offering type
- Software
- Cost components
- Personnel, Technology or R&D, Operations, Supply Chain
Revenue model
- B2B Healthcare/Pharma Partnerships: Products are provided free to patients; company generates revenue through partnerships with healthcare providers, clinical trial sponsors, and pharmaceutical companies for adverse event management solutions. Revenue appears to come from industry partners rather than patients.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Other | Annual | Free patient product with industry-funded model |
Go-to-market motion1 record
Distribution channels4 records
Marketing channels3 records
Alacrity Care product offering
Product offeringCore offering
Alacrity Care develops CloudOnc®, a first-in-class digital biomarker platform for immunotoxicity that enables precision technologies for toxicity prediction and personalized management of oncology therapeutics. The platform combines AI-powered analytics with connected wearables, spot assessment tools, and point-of-care blood analysis devices to deliver continuous remote monitoring, early adverse event detection, and 24/7 clinical support from licensed oncology practitioners. Products and clinical monitoring services are provided at no cost to oncology patients, with the company generating revenue through partnerships with healthcare providers, clinical trial sponsors, and pharmaceutical companies.
Product overview
Alacrity Care offers a unified product platform anchored by the CloudOnc® digital biomarker platform for immunotoxicity management. The platform integrates with a suite of connected medical devices (wearables, spot assessment tools, point-of-care blood analysis devices) to enable continuous patient monitoring. Additional service layers include 24/7 clinical support from licensed oncology practitioners, patient navigation services, and dedicated clinical trial support. The company provides all products at no cost to patients, with data flowing from 4G-enabled smartphones to a clinical portal for physician review.
Differentiator
Problem solved
Functional benefit
Brands
- CloudOnc®: First-in-class digital biomarker platform for immunotoxicity. Enables precision technologies for toxicity prediction and personalized management. The platform leverages wearables, spot assessment tools, and point-of-care blood analysis devices for monitoring specific adverse event detection needs.
Products and services
- CloudOnc® Digital Biomarker Platform First-in-class digital biomarker platform for immunotoxicity management in oncology. Enables precision technologies for toxicity prediction and personalized management through AI-powered analytics, real-world data collection, and continuous patient monitoring using connected wearables and point-of-care devices. Used by healthcare providers and clinical trial sponsors to monitor oncology patients, with products provided free to patients.
- Patient Monitoring Service Continuous remote monitoring program for cancer patients using provided medical devices. Includes 24/7 clinical support from licensed oncology practitioners and patient navigators for acute event escalation and seamless clinical integration, with products, devices, supplies, and replacements provided at no cost to patients.
- Clinical Trials Support Dedicated support service for patients enrolled in oncology clinical trials who are using Alacrity Care products, including direct contact with patient navigators for assistance and adverse event support during trial participation.
- Clinical Support Infrastructure 24/7 monitoring backend of licensed oncology practitioners that enables acute event escalation and seamless integration of Alacrity Care products into clinical settings, supporting oncologists and clinical staff in delivering continuous patient care.
Quantifiable outcome
- Detection of serious adverse events (SAEs) 6-12 hours ahead of current treatment paradigm
- +2 more outcomes
Companies that use Alacrity Care
Customer profileNamed customers1 record
Segments4 records
Ideal customer profiles2 records
Alacrity Care technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability4 records
Feature5 records
Alacrity Care partnerships and signals
Strategic signalScale indicators2 records
Recent moves6 records
Expansion highlights5 records
Alacrity Care competitors and assessment
Company assessmentBroad incumbents
- Flatiron Health: Oncology-specific EHR and real-world data business (acquired by Roche) widely used by community oncology practices and pharma for clinical and commercial evidence. Comparable in aggregating oncology patient data for adverse-event and outcomes insight at scale.
- Tempus Labs: Broad precision-oncology platform combining real-world data, AI and molecular profiling. Comparable as a data- and AI-enabled oncology platform that pharma partners with for evidence generation, but with a much wider portfolio than Alacrity's focused immunotoxicity play.
Emerging players
- WellDoc: Digital therapeutics and chronic-condition monitoring platform with FDA-cleared software. Comparable as a regulated, device- and data-driven platform that combines AI-based decision support with remote monitoring, but focused outside oncology.
Direct peers
- Vivify Health: Remote patient monitoring and virtual care platform combining connected devices with clinician workflows. Comparable technology stack (wearables + biometric feeds + clinical portal) and comparable B2B/enterprise selling motion into provider and payer customers.
- Kaiku Health: Digital health platform for cancer patient monitoring and symptom management, now part of Roche. Closely comparable offering in oncology RPM, patient-reported outcomes and integrations with wearables used during cancer treatment.
- Navigating Cancer: Oncology patient engagement and care management platform used by providers and patients across cancer treatment. Comparable in offering a digital companion experience for oncology patients and in selling into the same healthcare provider and pharma ecosystem.
- Carevive Systems: Oncology care planning and patient engagement platform with remote symptom monitoring. Comparable in addressing adverse-event capture and patient-reported outcomes for oncology practices, with similar enterprise provider and pharma customers.
- Noona Healthcare: Oncology patient-reported outcomes and remote symptom monitoring platform, now part of Elekta. Directly comparable to Alacrity's CloudOnc® in delivering digital symptom capture and adverse-event workflows for oncology patients and care teams.
- Medocity: Virtual care and remote patient monitoring platform with integrated device data and care-team dashboards. Comparable in multimodal device ingestion and continuous remote monitoring for chronic and post-acute patient populations.
Others
- Withings: Connected health device maker (scales, watches, blood pressure monitors, sleep mats) feeding structured biometric data into clinical platforms. Comparable as an enabling hardware layer in the same multi-modal RPM stack Alacrity uses, but operating as a device vendor rather than a clinical platform.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat4 records
Key risks6 records
Key highlights6 records
Customer concentration
Alacrity Care social profiles
Digital presenceAlacrity Care financial estimates
Financial estimateRevenue estimate
Valuation estimate
Alacrity Care leadership team
Management profileNumber of profiles
Profiles1 record
Alacrity Care funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Alacrity Care M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Alacrity Care
What does Alacrity Care do?
Alacrity Care develops CloudOnc®, a first-in-class digital biomarker platform for immunotoxicity that enables precision technologies for toxicity prediction and personalized management of oncology therapeutics. The platform combines AI-powered analytics with connected wearables, spot assessment tools, and point-of-care blood analysis devices to deliver continuous remote monitoring, early adverse event detection, and 24/7 clinical support from licensed oncology practitioners. Products and clinical monitoring services are provided at no cost to oncology patients, with the company generating revenue through partnerships with healthcare providers, clinical trial sponsors, and pharmaceutical companies.
Is Alacrity Care a public or private company?
Alacrity Care is a private company. It is classified as founder individual operated bootstrapped and is currently operating.
When was Alacrity Care founded?
Alacrity Care was founded in 2012. It employs 1 to 10 people.
Where is Alacrity Care based?
Alacrity Care is headquartered in Los Angeles, United States, in the North America region.
How does Alacrity Care make money?
One revenue line is on record: B2B Healthcare/Pharma Partnerships.
Who are Alacrity Care's main competitors?
Broad incumbents on record are Flatiron Health and Tempus Labs. WellDoc is listed as an emerging player. Direct peers are Vivify Health, Kaiku Health, Navigating Cancer, Carevive Systems, Noona Healthcare and Medocity. Withings is listed as an others.
Does Alacrity Care have an API?
No public API is recorded for Alacrity Care.
What industry is Alacrity Care in?
Alacrity Care's product category is Digital Health Oncology Platform. Its primary akta.pro industry code is HLALAFAD, Oncology Remote Symptom Monitoring & Care Navigation, with a secondary code of HLALAGAH, Oncology Telemedicine Platforms. Its NAICS code is 54151 and its SIC code is 8000.